1. Giannakakis, K, Faraggiana, T. Histopathology of lupus nephritis. Clin Rev Allergy Immunol 2011; 40: 170–180.
Google Scholar | Crossref | Medline2. Gao, J-j, Cai, G-y, Liu, S-w, et al Characteristics and influence factors of pathologic transformation in the subclasses of class IV lupus nephritis. Rheumatol Int 2012; 32: 1751–1759.
Google Scholar | Crossref | Medline3. Almaani, S, Meara, A, Rovin, BH. Update on Lupus Nephritis. Clin J Am Soc Nephrol 2017; 12: 825–835.
Google Scholar | Crossref | Medline | ISI4. Shum, K, Askanase, A. Treatment of lupus nephritis. Curr Rheumatol Rep 2011; 13: 283–290.
Google Scholar | Crossref | Medline5. Bryant, VL, Ma, CS, Avery, DT, et al. Cytokine-mediated regulation of human B cell differentiation into Ig-secreting cells: predominant role of IL-21 produced by CXCR5+ T follicular helper cells. J Immunol 2007; 179: 8180–8190.
Google Scholar | Crossref | Medline | ISI6. Sarra, M, Monteleone, G. Interleukin-21: a new mediator of inflammation in systemic lupus erythematosus. J Biomedicine Biotechnology 2010; 2010: 294582.
Google Scholar | Crossref | Medline7. Karnell, JL, Ettinger, R. The interplay of IL-21 and BAFF in the formation and maintenance of human B cell memory. Front Immunol 2012; 3: 2.
Google Scholar | Crossref | Medline8. Madbouly, NA, El-Hadad, G, El Amir, AM, et al. Hazard effects of chronic consumption of sucralose and saccharin-sodium cyclamate mixture in murine model. Egyptian Journal of Chemistry 2021; 189: 1747–1756. DOI:10.21608/ejchem.2021.99319.4622
Google Scholar | Crossref9. Farid, A, Tawfik, A, Elsioufy, B, et al. In vitro and in vivo anti-Cryptosporidium and anti-inflammatory effects of Aloe vera gel in dexamethasone immunosuppressed mice. International Journal for Parasitology: Drugs and Drug Resistance 2021; 17: 156–167.
Google Scholar | Crossref | Medline10. Farid, A, El-Dewak, M, Safwat, G, et al. Anti-apoptotic effect of melatonin protects spleen of whole body γ-irradiated male Sprague-Dawley rats. International Journal of Radiation Research 2021; 19(4): 861–872.
Google Scholar | Crossref11. Farid, A, Haytham, M, Essam, A, et al. Efficacy of the aqueous extract of Siwa dates in protection against the whole body γ irradiation induced damages in mice. Journal of Radiation Research and Applied Sciences 2021; 14(1): 322–335.
Google Scholar | Crossref12. Madbouly, N, El Amir, A, Kader, A, et al. The immunomodulatory activity of secnidazole-nitazoxanide in a murine cryptosporidiosis model. Journal of Medical Microbiology 2021; 70(3): 001327.
Google Scholar | Crossref | Medline13. Schneider, P, MacKay, F, Steiner, V, et al. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 1999; 189: 1747–1756.
Google Scholar | Crossref | Medline | ISI14. Morais, SA, Vilas-Boas, A, Isenberg, DA. B-cell survival factors in autoimmune rheumatic disorders. Ther Adv Musculoskelet Dis 2015; 7: 122–151.
Google Scholar | SAGE Journals | ISI15. Batten, M, Groom, J, Cachero, TG, et al. BAFF mediates survival of peripheral immature B lymphocytes. J Exp Med 2000; 192: 1453–1466.
Google Scholar | Crossref | Medline | ISI16. Vincent, FB, Kandane-Rathnayake, R, Hoi, AY, et al. Urinary B-cell-activating factor of the tumour necrosis factor family (BAFF) in systemic lupus erythematosus. Lupus 2018; 27: 2029–2040.
Google Scholar | SAGE Journals | ISI17. Hochberg, MC . Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725.
Google Scholar | Crossref | Medline18. Bombardier, C, Gladman, DD, Urowitz, MB, et al. Derivation of the sledai. A disease activity index for lupus patients. Arthritis Rheum 1992; 35: 630–640.
Google Scholar | Crossref | Medline19. Selim, ZI, Khader, TM, Mohammed, HO, et al. Urinary tumor necrosis factor-like weak inducer of apoptosis (uTWEAK) as a biomarker for lupus nephritis activity and its correlation with histolopathological findings of renal biopsy. The Egypt Rheumatologist 2019; 41: 19–23.
Google Scholar | Crossref20. Treamtrakanpon, W, Tantivitayakul, P, Benjachat, T, et al. APRIL, a proliferation-inducing ligand, as a potential marker of lupus nephritis. Arthritis Res Ther 2012; 14(6): R252.
Google Scholar | Crossref | Medline21. Hachiya, A, Karasawa, M, Imaizumi, T, et al. The ISN/RPS 2016 classification predicts renal prognosis in patients with first-onset class III/IV lupus nephritis. Scientific Rep 2021; 11: 1525.
Google Scholar | Crossref | Medline22. Farid, A, Abd Almolaa, T, Safwat, G. Complements as a predictive biomarker of lupus nephritis in female patients with systemic lupus erythematosus. Int J Cancer Biomed Res 2020; 4: 201–207.
Google Scholar23. Elamir, A, Farid, A, Amin, E, et al. Anti-nuclear antibody (ANA) patterns in egyptian systemic lupus erythematosus. J Egypt Soc Parasitol 2019; 49: 451–454.
Google Scholar | Crossref24. Farid, A, Eissa, R, Nada, A, et al. Serology of the systemic lupus erythematosus in Egyptian patients. J Egypt Soc Parasitol 2019; 49: 401–404.
Google Scholar | Crossref25. De Rosa, M, Rocha, AS, De Rosa, G, et al. Low-grade proteinuria does not exclude significant kidney injury in lupus nephritis. Kidney Int Rep 2020; 5(7): 1066–1068.
Google Scholar | Crossref | Medline26. Elsaid, D, Abdel Noor, R, Shalaby, K, et al. Urinary tumor necrosis factor-like weak inducer of apoptosis (uTWEAK) and urinary monocyte chemo-attractant protein-1 (uMCP-1): Promising biomarkers of lupus nephritis activity? Saudi J Kidney Dis Transplant 2021; 32: 19–29.
Google Scholar | Crossref | Medline27. Wong, CK, Wong, PTY, Tam, LS, et al. Elevated production of B cell chemokine CXCL13 is correlated with systemic lupus erythematosus disease activity. J Clin Immunol 2010; 30(1): 45–52.
Google Scholar | Crossref | Medline28. Ahmed, YM, Erfan, DM, Hafez, SF, et al. The association of single nucleotide polymorphism of interleukin-21 gene and serum interleukin-21 levels with systemic lupus erythematosus. Egypt J Med Hum Genet 2017; 18: 129–136.
Google Scholar | Crossref29. Dolff, S, Abdulahad, WH, Westra, J, et al. Increase in IL-21 producing T-cells in patients with systemic lupus erythematosus. Arthritis Res Ther 2011; 13(5): R157.
Google Scholar | Crossref | Medline | ISI30. Jacquemin, C, Schmitt, N, Contin-Bordes, C, et al. OX40 Ligand contributes to human lupus pathogenesis by promoting T follicular helper response. Immunity 2015; 42: 1159–1170.
Google Scholar | Crossref | Medline31. Nakou, M, Papadimitraki, ED, Fanouriakis, A, et al. Interleukin-21 is increased in active systemic lupus erythematosus patients and contributes to the generation of plasma B cells. Clin Experimental Rheumatology 2013; 31: 172–179.
Google Scholar | Medline32. Pan, H-F, Wu, G-C, Fan, Y-G, et al. Decreased serum level of IL-21 in new-onset systemic lupus erythematosus patients. Rheumatol Int 2013; 33: 2337–2342.
Google Scholar | Crossref | Medline33. Dolff, S, Scharpenberg, C, Specker, C, et al. IL-22 production of effector CD4+ T-cells is altered in SLE patients. Eur J Med Res 2019; 24: 24.
Google Scholar | Crossref | Medline34. Moore, PA, Belvedere, O, Orr, A, et al. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 1999; 285: 260–263.
Google Scholar | Crossref | Medline | ISI35. Schneider, P . The role of APRIL and BAFF in lymphocyte activation. Curr Opin Immunol 2005; 17: 282–289.
Google Scholar | Crossref | Medline | ISI36. Marsters, SA, Yan, M, Pitti, RM, et al. Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI. Curr Biol 2000; 10: 785–788.
Google Scholar | Crossref | Medline37. Stein, JV, López-Fraga, M, Elustondo, FA, et al. APRIL modulates B and T cell immunity. J Clin Invest 2002; 109: 1587–1598.
Google Scholar | Crossref | Medline38. Koyama, T, Tsukamoto, H, Miyagi, Y, et al. Raised serum APRIL levels in patients with systemic lupus erythematosus. Ann Rheum Dis 2005; 64: 1065–1067.
Google Scholar | Crossref | Medline | ISI39. Vincent, F, Northcott, M, Hoi, A, et al. Association of serum B cell activating factor from the tumour necrosis factor family (BAFF) and a proliferation-inducing ligand (APRIL) with central nervous system and renal disease in systemic lupus erythematosus. Lupus 2013; 22: 873–884.
Google Scholar | SAGE Journals | ISI40. Sfar, I, Dhaouadi, T, Turki, S, et al. BAFF promoter polymorphisms and serum levels in Tunisian patients with systemic lupus erythematosus. Rheumatology (Sunnyvale) 2014; S4: 003.
Google Scholar41. Collins, CE, Gavin, AL, Migone, TS, et al. B lymphocyte stimulator (BLyS) isoforms in systemic lupus erythematosus: disease activity correlates better with blood leukocyte BLyS mRNA levels than with plasma BLyS protein levels. Arthritis Research Therapy 2006; 8: R6.
Google Scholar | Crossref | Medline | ISI42. Stohl, W, Metyas, S, Tan, S-M, et al. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: Longitudinal observations. Arthritis Rheum 2003; 48: 3475–3486.
Google Scholar | Crossref | Medline43. Stohl, W, Metyas, S, Tan, SM, et al. Inverse association between circulating APRIL levels and serological and clinical disease activity in patients with systemic lupus erythematosus. Ann Rheum Dis 2004; 63: 1096–1103.
Google Scholar | Crossref | Medline | ISI44. Petri, M, Stohl, W, Chatham, W, et al. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum 2008; 58(8): 2453–2459.
Google Scholar | Crossref | Medline45. Morel, J, Roubille, C, Planelles, L, et al. Serum levels of tumour necrosis factor family members a proliferation-inducing ligand (APRIL) and B lymphocyte stimulator (BLyS) are inversely correlated in systemic lupus erythematosus. Ann Rheum Dis 2009; 68: 997–1002.
Google Scholar | Crossref | Medline | ISI46. Hegazy, M, Darwish, H, Darweesh, H, et al. Raised serum level of APRIL in patients with systemic lupus erythematosus: correlations with disease activity indices. Clin Immunol 2010; 135: 118–124.
Google Scholar | Crossref | Medline | ISI47. Aguirre-Valencia, D, Ríos-Serna, LJ, Posso-Osorio, I, et al. Expression of BAFF, APRIL, and cognate receptor genes in lupus nephritis and potential use as urinary biomarkers. J Translational Autoimmunity 2019; 3: 100027.
Google Scholar | Crossref | Medline48. Lalwani, P, de Souza, GKBB, de Lima, DSN, et al. Serum thiols as a biomarker of disease activity in lupus nephritis. PLoS One 2015; 10: e0119947.
Google Scholar | Crossref | Medline49. Feng, X, Wang, D, Chen, J, et al. Inhibition of aberrant circulating Tfh cell proportions by corticosteroids in patients with systemic lupus erythematosus. PLoS One 2012; 7: e51982.
Google Scholar | Crossref | Medline |